Fracture risk assessment using FRAX prior to dual energy densitometry (DXA) for patients taking aromatase inhibitor therapies
Association of Breast Surgery ePoster Library. Mullen R. 05/15/17; 166217; P033
Russell Mullen
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Rate & Comment (0)
Introduction: Aromatase inhibitor (AI) therapy is a well-established adjuvant treatment in oestrogen receptor positive breast cancer. It is however associated with an increased risk of osteoporotic fracture, therefore clinicians are recommended to make an assessment of fracture risk at baseline using bone dual energy densitometry (DXA) to estimate Bone Mineral Density (BMD). Recent guidelines recommend fracture risk assessment prior to DXA. Currently all patients started on an AI in our unit receive a DXA. This study aimed to assess if the use of the FRAX scoring system could identify patients who did not require a DXA.
Methods: Retrospective analysis of 100 patients taking AI who had previously undergone DXA was conducted. FRAX score (www.shef.ac.uk/frax) was carried out for all patients. FRAX score of >10% indicated DXA scan. It was assessed if FRAX score correctly identified patient who subsequently requires anti-osteoporosis treatment.
Methods: Retrospective analysis of 100 patients taking AI who had previously undergone DXA was conducted. FRAX score (www.shef.ac.uk/frax) was carried out for all patients. FRAX score of >10% indicated DXA scan. It was assessed if FRAX score correctly identified patient who subsequently requires anti-osteoporosis treatment.
Introduction: Aromatase inhibitor (AI) therapy is a well-established adjuvant treatment in oestrogen receptor positive breast cancer. It is however associated with an increased risk of osteoporotic fracture, therefore clinicians are recommended to make an assessment of fracture risk at baseline using bone dual energy densitometry (DXA) to estimate Bone Mineral Density (BMD). Recent guidelines recommend fracture risk assessment prior to DXA. Currently all patients started on an AI in our unit receive a DXA. This study aimed to assess if the use of the FRAX scoring system could identify patients who did not require a DXA.
Methods: Retrospective analysis of 100 patients taking AI who had previously undergone DXA was conducted. FRAX score (www.shef.ac.uk/frax) was carried out for all patients. FRAX score of >10% indicated DXA scan. It was assessed if FRAX score correctly identified patient who subsequently requires anti-osteoporosis treatment.
Methods: Retrospective analysis of 100 patients taking AI who had previously undergone DXA was conducted. FRAX score (www.shef.ac.uk/frax) was carried out for all patients. FRAX score of >10% indicated DXA scan. It was assessed if FRAX score correctly identified patient who subsequently requires anti-osteoporosis treatment.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}